Edition:
United States

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.68USD
4:00pm EDT
Change (% chg)

$-0.02 (-2.43%)
Prev Close
$0.70
Open
$0.70
Day's High
$0.70
Day's Low
$0.68
Volume
31,774
Avg. Vol
135,974
52-wk High
$4.78
52-wk Low
$0.62

Latest Key Developments (Source: Significant Developments)

Trovagene reports positive data from a preclinical in-vivo study examining combination of their plk1 inhibitor with investigational flt3 inhibitor
Wednesday, 16 Aug 2017 08:00am EDT 

Aug 16 (Reuters) - Trovagene Inc ::Trovagene's plk1 inhibitor pcm-075, in preclinical aml data, significantly enhances the efficacy of a flt3 inhibitor in combination therapy.Trovagene Inc - positive data from a preclinical in-vivo study examining combination of their plk1 inhibitor, pcm-075, with investigational flt3 inhibitor.  Full Article

Trovagene Q2 loss per share $0.26
Wednesday, 9 Aug 2017 04:27pm EDT 

Aug 9 (Reuters) - Trovagene Inc ::Trovagene announces second quarter 2017 company highlights and financial results.Q2 loss per share $0.26.  Full Article

Trovagene, Antonius Schuh and Stephen Zaniboni resolve employment dispute
Friday, 28 Jul 2017 05:36pm EDT 

July 28 (Reuters) - Trovagene Inc :Trovagene, Antonius Schuh and Stephen Zaniboni resolve employment dispute.Trovagene Inc - Co,‍ Antonius Schuh, Stephen Zaniboni, co's former CEO,former CFO, resolved their respective legal claims against each other​.  Full Article

Trovagene announces peer-reviewed publication of first-in-human phase 1 trial results with PCM-075
Tuesday, 25 Jul 2017 08:00am EDT 

July 25 (Reuters) - Trovagene Inc :Trovagene announces peer-reviewed publication of first-in-human phase 1 trial results with pcm-075, its polo-like kinase 1 (plk1) inhibitor.Trovagene inc says data from first-in-human trial demonstrated that pcm-075 is generally safe and well-tolerated in patients with advanced cancers.  Full Article

Sabby Management reports 5.70 percent passive stake in Trovagene
Monday, 17 Jul 2017 03:01pm EDT 

July 17 (Reuters) - Trovagene Inc :Sabby Management LLC reports 5.70 percent passive stake in Trovagene Inc as of July 13 - sec filing.  Full Article

Trovagene announces agreement with Novogene
Wednesday, 12 Jul 2017 08:00am EDT 

July 12 (Reuters) - Trovagene Inc ::Trovagene announces agreement with Novogene for NextCollect in China.Trovagene Inc- ‍first shipments of NextCollect are planned for July 2017​.Trovagene-‍Novogene will buy NextCollect, Trovagene's proprietary urine collection and nucleic acid preservation device for validation in Chinese market​.Trovagene - will sell Novogene NextCollect urine collection and stabilization device, in addition to reagents and methods to extract cell-free DNA from urine.  Full Article

Trovagene engages PRA Health Sciences to conduct phase 1b/2 trial of PCM-075
Thursday, 6 Jul 2017 08:00am EDT 

July 6 (Reuters) - Trovagene Inc :Trovagene engages leading cro in aml to conduct phase 1b/2 trial of pcm-075.  Full Article

Trovagene Inc announces deal with Nerpharma
Thursday, 29 Jun 2017 08:00am EDT 

June 29 (Reuters) - Trovagene Inc ::Trovagene announces manufacturing agreement with Nerpharma for supply of PCM-075 for AML trial.Trovagene - agreement covers clinical, commercial supply of PCM-075 for co, includes both active pharmaceutical ingredients, GMP production of capsules.Trovagene Inc - plans to initiate a phase 1B/2 clinical trial in patients with acute myeloid leukemia (AML).  Full Article

Trovagene announces submission of investigational NDA to initiate trial of PCM-075
Tuesday, 27 Jun 2017 08:00am EDT 

June 27 (Reuters) - Trovagene Inc :Trovagene announces submission of investigational new drug application to initiate phase 1B/2 clinical trial of PCM-075 for acute myeloid leukemia.Trovagene plans to initiate clinical trials of PCM-075 in AML.Have IND and protocol for phase 1B/2 clinical trial submitted and under review by FDA.  Full Article

Trovagene receives notice of event of default with respect to certain loan and security agreement
Friday, 23 Jun 2017 05:15pm EDT 

June 23 (Reuters) - Trovagene Inc -:Trovagene Inc- on June 20, received notice of event of default with respect to certain loan and security agreement dated as of November 17, 2015.Trovagene Inc- equipment notice stated that events of default had occurred and are continuing - sec filing.Trovagene Inc- svb intends to monitor default situation and will decide whether or not to exercise rights and remedies.  Full Article

BRIEF-Trovagene appoints Athena Countouriotis to its board of directors

* Trovagene strengthens board of directors with appointment of oncology development veteran Dr. Athena Countouriotis Source text for Eikon: Further company coverage: